Drug Approval | October 13, 2021
Dr Reddy’s launch anti-cancer drug in China
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
The Pune centre expands its presence beyond Bangalore and Hyderabad
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
